A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2

PURPOSE: Administering the best treatment after failure of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy requires knowledge of resistance status. In this trial, treatment efficacy of osimertinib was assessed in patients with non-small cell lung carcinoma (NSCLC) har...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Cheol-Kyu, Cho, Hyun-Ju, Choi, Yoo-Duk, Oh, In-Jae, Kim, Young-Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473264/
https://www.ncbi.nlm.nih.gov/pubmed/30189719
http://dx.doi.org/10.4143/crt.2018.387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473264/
https://www.ncbi.nlm.nih.gov/pubmed/30189719
http://dx.doi.org/10.4143/crt.2018.387

Ejemplares similares